TNFRSF8 and mature T-cell and NK-cell non-Hodgkin lymphoma: The combination of BV with doxorubicin-based chemotherapy (BV-CHP) is now FDA approved for the front-line treatment of CD30-expressing peripheral T-cell lymphomas (PTCL) [8,9].